Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

A 27-year-old has been left unable to drink chilled beverages or exercise outdoors in winter after developing a rare cold ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Hanna Newnham, 27, from Brighton, first noticed symptoms of cold urticaria - hives that appear after cold temperature ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Morgan Stanley initiated coverage of Celldex (CLDX) with an Overweight rating and $46 price target Celldex is developing antibodies for ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

For Hanna Newnham, 27, her one time McDonald's favourites are now completely off limits as is exercising outdoors during the ...